Comparative Pharmacology
Head-to-head clinical analysis: SEGLENTIS versus STIE CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEGLENTIS versus STIE CORT.
SEGLENTIS vs STIE-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEGLENTIS is a fixed-dose combination of the opioid oxycodone and the opioid antagonist naltrexone. Oxycodone acts as a mu-opioid receptor agonist, providing analgesia. Naltrexone is intended to reduce the abuse potential of oxycodone by blocking opioid receptors when the drug is tampered with (e.g., crushed or chewed), but is sequestered in the core of the tablet and not released when taken orally as directed.
Glucocorticoid receptor agonist; modulates gene expression leading to anti-inflammatory and immunosuppressive effects.
Subcutaneous injection: 300 mg (1.5 mL) once weekly. Administer in combination with oral capecitabine.
Topical: Apply a thin film to affected area twice daily. Maximum 2-week continuous use. In severe cases, apply up to 4 times daily. Do not exceed 50 g/week.
None Documented
None Documented
The terminal elimination half-life of celecoxib is approximately 11 hours; for tramadol, it is about 6 hours, and for its active M1 metabolite, about 7 hours. Clinically, this supports twice-daily dosing for Seglentis (two tablets BID).
Terminal elimination half-life is 1.5-2 hours (intravenous) and 2-3 hours (oral), reflecting rapid clearance; clinical context: supports twice-daily dosing for systemic effects.
Seglentis (celecoxib and tramadol) is primarily excreted renally. Celecoxib is eliminated via hepatic metabolism (CYP2C9) with <3% excreted unchanged in urine; fecal excretion accounts for approximately 70% of an oral dose (as metabolites). Tramadol and its active metabolite (M1) are mainly excreted renally (about 90% of the dose, with 30% unchanged tramadol and 15% M1); the remainder is excreted fecally.
Renal: 60-70% as metabolites; biliary/fecal: 20-30% as metabolites; unchanged drug: <5%.
Category C
Category C
Corticosteroid
Corticosteroid